Souhaitez-vous accéder aux communiqués récents ?

On Aug 14, 2025, Fly-E reported a 32% revenue drop and weak E-Bike sales tied to battery issues, causing its stock to plunge 87% from $7.76 to $1.00.

On May 27, 2025, Savara revealed the FDA refused to file its MOLBREEVI BLA due to insufficient CMC data, causing shares to fall $0.90, or 31.69%, to $1.94.

On Oct 24, 2025, Beyond Meat disclosed a material impairment charge, dropping shares 23%. On Nov 3, 2025, it delayed Q3 results, causing further decline.

Yimutian plans to acquire 100% of Xunxi Technology’s equity through a combination of cash and stock.

The lawsuit alleges Quantum improperly recognized revenue and must restate financials, rendering prior statements false and causing investor losses.

Alvotech got an FDA Complete Response Letter for its AVT05 BLA after a failed July 2025 inspection; shares fell 34% to $5.03 on the news.

uniQure disclosed the FDA no longer agrees its AMT-130 trial data may support a BLA submission, making timing unclear. Shares fell over 57% on the news.

Allegedly, defendants hid unauthorized FDA design changes to DexCom’s G6 and G7, making them less reliable and exposing users to health risks.

Stride, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.

Grindr Inc. shareholders are encouraged to contact BFA Law about its investigation into the take-private transaction.